- Home
- AMTB vs ADPT Comparison
AMTB vs ADPT Comparison
Compare AMTB & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMTB
- ADPT
- Stock Information
- Founded
- AMTB 1979
- ADPT 2009
- Country
- AMTB United States
- ADPT United States
- Employees
- AMTB N/A
- ADPT N/A
- Industry
- AMTB Major Banks
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMTB Finance
- ADPT Health Care
- Exchange
- AMTB Nasdaq
- ADPT Nasdaq
- Market Cap
- AMTB 940.3M
- ADPT 929.8M
- IPO Year
- AMTB N/A
- ADPT 2019
- Fundamental
- Price
- AMTB $22.69
- ADPT $7.45
- Analyst Decision
- AMTB Buy
- ADPT Buy
- Analyst Count
- AMTB 6
- ADPT 4
- Target Price
- AMTB $27.40
- ADPT $6.75
- AVG Volume (30 Days)
- AMTB 219.7K
- ADPT 1.3M
- Earning Date
- AMTB 01-22-2025
- ADPT 02-12-2025
- Dividend Yield
- AMTB 1.60%
- ADPT N/A
- EPS Growth
- AMTB N/A
- ADPT N/A
- EPS
- AMTB N/A
- ADPT N/A
- Revenue
- AMTB $255,637,000.00
- ADPT $177,282,000.00
- Revenue This Year
- AMTB N/A
- ADPT $6.48
- Revenue Next Year
- AMTB $13.47
- ADPT $18.72
- P/E Ratio
- AMTB N/A
- ADPT N/A
- Revenue Growth
- AMTB N/A
- ADPT N/A
- 52 Week Low
- AMTB $18.54
- ADPT $2.28
- 52 Week High
- AMTB $27.00
- ADPT $7.50
- Technical
- Relative Strength Index (RSI)
- AMTB 53.12
- ADPT 61.48
- Support Level
- AMTB $21.65
- ADPT $5.98
- Resistance Level
- AMTB $22.40
- ADPT $7.28
- Average True Range (ATR)
- AMTB 0.63
- ADPT 0.56
- MACD
- AMTB 0.16
- ADPT 0.04
- Stochastic Oscillator
- AMTB 91.94
- ADPT 96.86
About AMTB Amerant Bancorp Inc.
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices, and telephones.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).